China Pharma (CPHI) 10-K2022 FY Annual report

Filed: 30 Mar 23, 4:54pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: admitted, AHFCAA, aspect, atomization, banned, Bonier, CDP, certify, Chengdu, coexistence, compulsory, consecutive, constitute, contrary, convicted, creation, Deng, digital, disqualify, dominated, dysmenorrhea, enriched, fashion, fastest, FIE, filling, fractional, green, HFCAA, idea, imitation, interval, interview, invention, isolation, Ke, lay, led, loosed, mainland, MIC, misrepresentation, mutant, NBS, Omicron, ophthalmic, oxygen, pathogenicity, Perfecting, PIPL, popular, popularized, post, pre, prelude, proactively, Protocol, rare, Region, retroactively, reverse, rulemaking, run, Senate, sharp, simple, Soliciting, split, squeezed, stop, surged, testimony, thee, tying, unchanged, user, vacate, verification, voluntary, waiting, web, witnessed, worsen, writing

Removed: achieved, altered, austere, combat, conform, curb, decentralization, deposit, disabled, dismissal, dismissing, downturn, dropped, emphasize, excessively, expansive, floating, formally, inconsistent, ineffectual, inflation, nationalization, owing, put, readjustment, recentralization, Reclassification, refined, refinement, shown, sick, spread, tariff, terminate, travel, unemployment, unprecedented, upgraded, wealth, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CPHI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.11

Loans Extension Confirmation Letter

Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD152,577.99 respectively as of December 31, 2022. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui and the Company agreed to extend the loans to December 31, 2023, by which date the Company shall repay the principal and accumulated interest.

	Lender:	/s/ Heung Mei Tsui

	Borrower:	China Pharma Holdings, Inc.

	By:	/s/ Zhilin Li, President & CEO

	Date:	December 31, 2022